Affiliation:
1. Department of Pharmaceutical Technology, Laboratory of Drug Design and Discovery, Jadavpur University, Kolkata,
700032, India
2. Department of Pharmaceutical Technology, Natural Science Laboratory, Division of Medicinal and
Pharmaceutical Chemistry, Jadavpur University, Kolkata, 700032, India
Abstract
Abstract:
HDAC9 is a histone deacetylase enzyme belonging to the class IIa of HDACs which catalyses
histone deacetylation. HDAC9 inhibit cell proliferation by repairing DNA, arresting the cell
cycle, inducing apoptosis, and altering genetic expression. HDAC9 plays a significant part in human
physiological system and are involved in various type of diseases like cancer, diabetes, atherosclerosis
and CVD, autoimmune response, inflammatory disease, osteoporosis and liver fibrosis. This review
discusses the role of HDAC9 in different diseases and structure-activity relationships (SARs)
of various hydroxamate and non-hydroxamate-based inhibitors. SAR of compounds containing several
scaffolds have been discussed in detail. Moreover, structural requirements regarding the various
components of HDAC9 inhibitor (cap group, linker and zinc-binding group) has been highlighted in
this review. Though, HDAC9 is a promising target for the treatment of a number of diseases including
cancer, a very few research are available. Thus, this review may provide useful information for
designing novel HDAC9 inhibitors to fight against different diseases in the future.
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmacology,General Medicine
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献